DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy.

Author(s): Koytak A, Erol K, Coskun E, Asik N, Ozturk H, Ozerturk Y

Affiliation(s): Kartal Training and Research Hospital, 2nd Eye Clinic, Cevizli, Istanbul, Turkey. akoytak@yahoo.com

Publication date & source: 2010-11, Retina., 30(10):1698-703.

PURPOSE: The purpose of this study was to evaluate the results of fluorescein angiography-guided photodynamic therapy with half-dose verteporfin in the treatment of chronic central serous chorioretinopathy with focal leakage areas. METHODS: Eight cases with a history of central serous chorioretinopathy of >/=6 months were included. All eyes had one or more focal areas of active retinal pigment epithelial leak. Photodynamic therapy was applied with half-dose verteporfin (3 mg/m(2)), and the spot size was set limited to the area of active leakage shown on fluorescein angiography. RESULTS: The mean duration of the last central serous chorioretinopathy episode was 12.50 months. The mean best-corrected visual acuity improved from 20/122 to 20/60 the first month (P = 0.017) and to 20/55 the first year after treatment (P = 0.018). Seven eyes (87.5%) had improved vision 1 year after treatment, and 1 eye (12.5%) had stable vision with a mean number of 3.61 gained lines. The mean central macular thickness was reduced from 366 +/- 95 mum to 217 +/- 32 mum the first month (P = 0.006). CONCLUSION: Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin seems to be a rational and effective alternative to other methods in the treatment of chronic central serous chorioretinopathy with focal leakage on fluorescein angiography.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017